DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging
PR Newswire•11/11/2026•07:00 ET
0
Key Highlights
- ➤Castle Biosciences (CSTL) presented DecisionDx-Melanoma data at SDPA and Dermato-Onco2026
- ➤T1a study identified elevated-risk patients in 12% of thin-melanoma cases
- ➤Five-year melanoma-specific survival was 97.1% for Class 1A versus 86.2% for Class 2B
- ➤i31-ROR low-risk patients had 92.5% five-year recurrence-free survival versus 54.2% high-risk
- ➤i31-ROR low-risk patients had 98.4% five-year melanoma-specific survival versus 81.6% high-risk
Expert Statements
Harrison Nguyen, Study author and board-certified dermatologist at Harrison Dermatology and Research Group
“A thin melanoma may be reassuring, but these findings remind us that some of those patients still face a higher risk of dying from their disease.”
Harrison Nguyen, Study author and board-certified dermatologist at Harrison Dermatology and Research Group
“The additional prognostic information provided by DecisionDx-Melanoma can help us explain to patients why we may recommend closer follow-up, even when their tumor's traditional features appear favorable.”
DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging PR Newswire
SDPA analysis demonstrates DecisionDx-Melanoma can identify higher-risk patients within a traditionally low-risk population with thin melanomas
Get started
Create a free account to read the full story.